Herpes zoster vaccine shown to be safe in patients with rheumatoid arthritis.
Researchers found that one-third of patients remain in remission after discontinuing tofacitinib and that low baseline RF titers predict low disease activity after tofacitinib discontinuation.
Investigators conduct a systematic review to evaluate the risks and benefits of biologics as monotherapy or in combination with methotrexate in patients with rheumatoid arthritis who have not responded to previous biologic treatment.
Twelve-month trial compared tofacitinib with adalimumab as monotherapy or in combination with methotrexate.
Results were announced from a phase 3 trials assessing safety and efficacy of tofacitinib citrate for active psoriatic arthritis
Rheumatology Advisor Articles
- Topical vs Oral NSAIDs for Rheumatoid Arthritis: Examining Cardiovascular Risks
- Update: 2017 Treat-to-Target Recommendations for Spondyloarthritis
- Risk for COPD, Asthma Examined in Women With Rheumatoid Arthritis
- Host Genetics May Affect Intestinal Microbiota Composition in Reactive Arthritis
- Introduction of bDMARDs Linked to Reduced Incidence of Total Knee Replacement
- Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
- Managing Treatment Nonadherence in Rheumatic Diseases
- Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes
- Routine Vitamin D, Calcium Supplementation Not Associated With Fracture Reduction in Older Adults
- Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis
- Assessment of Nitrated Nucleosome Levels and Neuropsychiatric Events in Systemic Lupus Erythematosus
- Clinicians Who Share Email Addresses With Patients Have Higher Satisfaction Scores
- Biosimilar LBEC0101 Equivalent to ETN-RP for RA Unresponsive to Methotrexate
- Adalimumab Demonstrated Superior Efficacy Over Standard of Care in Refractory Uveitis
- Clinician Counseling for Exercise Increased Among Adults With Arthritis Between 2002 and 2014